Core Viewpoint - Lixte Biotechnology Holdings, Inc. has successfully closed a private placement raising approximately $5.0 million through the sale of shares and warrants, aimed at supporting its cancer drug development efforts [1][3]. Group 1: Private Placement Details - The offering included the sale of 2,382,084 shares of Common Stock (or Pre-Funded Warrants), 3,573,130 shares of Series B Convertible Preferred Stock, and 6,355,214 Common Warrants [2]. - The Pre-Funded Warrants are immediately exercisable at a price of $0.00001, while the Common Warrants have an initial exercise price of $1.00 per share and expire 60 months after the resale registration statement is effective [2]. - The gross proceeds of approximately $5.0 million consist of $4.0 million paid at closing and $1.0 million to be paid upon the effectiveness of the resale registration statement [3]. Group 2: Use of Proceeds - The net proceeds from the offering, along with existing cash, are intended for general corporate purposes and working capital [3]. Group 3: Company Overview - Lixte Biotechnology Holdings, Inc. is a clinical-stage pharmaceutical company focused on developing new cancer therapies, particularly its lead compound LB-100, which has shown promise in enhancing chemotherapy and immunotherapy outcomes [6][7]. - LB-100 is part of a new treatment paradigm in cancer biology known as activation lethality, with ongoing proof-of-concept clinical trials for various cancer types [7].